327 results on '"Vigouroux, S"'
Search Results
2. Vascularite systémique sévère induite par l’ibrutinib
3. Vascularite systémique sévère induite par l’ibrutinib
4. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas
5. Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord
6. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes
7. Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review
8. Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC
9. Allogeneic stem cell transplantation for acute myeloid leukemia with normal cytogenetics (CN-AML): outcome, risk factors and role of molecular subgroups in 1006 patients - a report from the Acute Leukemia Working Party of EBMT [Abstract]
10. Occurrence of graft‐versus‐host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT
11. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT
12. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
13. Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire
14. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?
15. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM
16. Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
17. Student mental health during the first two years of the COVID- 19 pandemic
18. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
19. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
20. Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation
21. Effet d'interventions en Self-Help : Exemples en psychologie positive et en pleine conscience
22. Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation
23. In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?
24. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation
25. Allogreffes à conditionnement atténué dans les hémopathies lymphoïdes
26. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation
27. Quick and cheap technique to cryopreserve Welsh pony embryo
28. IMPACT OF FEMALE DONOR ON ALLOGENEIC STEM CELL TRANSPLANTATION OUTCOME OF MALE RECIPIENT AFTER T-CELL DEPLETION BY RABBIT ANTITHYMOCYTE GLOBULIN: PH-P380
29. RISK FACTORS FOR STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FROM MATCHED RELATED OR UNRELATED DONORS: PH-P378
30. IMPACT OF THE INTENSITY OF THE PROPHYLACTIC IMMUNOSUPPRESSIVE THERAPY IN HLA IDENTICAL ALLOGENEIC STEM CELL TRANSPLANTATION FOR CR1 AML CONDITIONED WITH A FLUDARABINE- IV BUSULFAN REGIMEN: A RETROSPECTIVE STUDY OF THE ALWP OF THE EBMT: PH-O147
31. ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA WITH NORMAL CYTOGENETICS (CN-AML): OUTCOME, RISK FACTORS AND ROLE OF MOLECULAR SUBGROUPS IN 1006 PATIENTS - A REPORT FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT: PH-O127
32. EFFECT OF IMMUNOMODULATION FOR PERIPHERAL T-CELL LYMPHOMA IN RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT:A SFGM-TC STUDY ON 64 PATIENTS: PH-O112
33. Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response
34. Fludarabine, IV busulfan and antithymocyte globulinsbased reduced-toxicity conditioning regimen (FB3) prior to allogeneic stem cell transplantation (allo-SCT): results of a multicentre prospective trial: O378
35. Pre-transplantation risk factors for the development of sclerotic chronic GvHD after allogeneic HSCT: A multicentre retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC): O326
36. In vivo T-cell depletion with ATG or alemtuzumab prevents GVHD without affecting leukaemia-free-survival in AML patients in CR1 given PBSC from HLA-identical sibling after chemotherapy-based RIC. A survey from the Acute Leukemia Working Party of the EBMT: O316
37. Cancer vaccines: dream, reality, or nightmare?
38. Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy
39. Romiplostim (AMG531, Nplate) for secondary failure of platelet recovery after allo-SCT
40. A phase II study of Yttrium-90-ibritumomab tiuxetan in combination with a fludarabine-based reduced-intensity regimen followed by allogenic stem cell transplantation in patients with relapsed or chemorefractory CD 20 positive non-Hodgkinʼs lymphoma: P965
41. Similar outcome after related or unrelated allogeneic stem cell transplantation following reduced conditioning with fludarabine, busulfan, and antithymocyte globulin: P980
42. Allograft after paediatric-inspired therapy does not improve young patientʼs outcome with high-risk Philadelphia-chromosome-negative acute lymphoblastic leukaemia. A single-centre report: P921
43. Haemophagocytic syndrome after allogeneic haematopoietic cell transplantation: more a graft-rejection than an infectious process?: P744
44. Bronchiolitis obliterans after allogeneic stem cell transplantation: a single-centre retrospective study of risk factors: P655
45. CD4+CD25+ regulatory T-cell depletion to improve graftversus- tumour effect after donor lymphocytes infusion: biological predictors of clinical response: O291
46. Reduce-intensity conditioning regimen prior to unrelated cord blood transplantation in patients with acute myeloid leukaemia: a prospective phase II multicentric trial of the Société Française de Greffe de Moelle et Thérapie Cellulaire and Eurocord: O159
47. Crystal Structure of the PBP/SBP MotA in complex with glucopinic acid from A. tumefaciens B6/R10
48. Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC): O161
49. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15
50. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.